Search Results
Results found for empty search
- New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment | Dr. GPCR Ecosystem
Home → Flash News → New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Published on June 10, 2025 Category Dr. GPCR Podcast New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Recent Articles Previous Next
- Adenosine A3 receptor has been proposed to have significant roles in metabolism and immune responses. Check out this study to understand how it affects metabolic dysfunction-associated steatotic liver progression. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://buff.ly/42b6ra3 #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Adenosine A3 receptor has been proposed to have significant roles in metabolism and immune responses. Check out this study to understand how it affects metabolic dysfunction-associated steatotic liver progression. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://buff.ly/42b6ra3 #gpcr #drgpcr Published on January 16, 2025 Category GPCR Weekly News Adenosine A3 receptor has been proposed to have significant roles in metabolism and immune responses. Check out this study to understand how it affects metabolic dysfunction-associated steatotic liver progression. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a3ar-antagonism-mitigates-metabolic-dysfunction-associated-steatotic-liver-disease-by-exploiting-monocyte-derived-kupffer-cell-necroptosis-and-inflammation-resolution #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- Seeking to gain more knowledge on signaling bias? We’ve got the perfect opportunity for you 🚀 Registrations open until February 14th ⚠️ Last spots available for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin ✳️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Seeking to gain more knowledge on signaling bias? We’ve got the perfect opportunity for you 🚀 Registrations open until February 14th ⚠️ Last spots available for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin ✳️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 8, 2025 Category Dr. GPCR Courses Seeking to gain more knowledge on signaling bias? We’ve got the perfect opportunity for you 🚀 Registrations open until February 14th ⚠️ Last spots available for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin ✳️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- master gpcr pharmacologic models before its too late | Dr. GPCR Ecosystem
Home → Flash News → master gpcr pharmacologic models before its too late Published on July 11, 2025 Category GPCR Weekly News Most GPCR teams aren’t failing because of bad science. They’re stalling because of slow decisions, misapplied models, and buried priorities. This week’s GPCR Weekly News helps you fix that. Terry’s Corner breaks down the 4 pharmacologic models that separate forecasting from guessing. Dr. Sokhom S. Pin shares how he built high-output, low-burnout teams—and earned his PhD while working full time. Yamina’s Corner exposes the silent drift killing GPCR programs (and how to reverse it). 💡Plus: New tools from Celtarys Research . Biotech strategy moves from Catalio Capital Management . And your voice in our survey. If your competitors are already applying these insights… can you afford to skip this week’s update? ✳️ Read the Weekly News → https://www.ecosystem.drgpcr.com/post/crush-data-confusion-conquer-gpcr-drug-discovery?utm_content=bufferd9b30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #GPCR #Pharmacology #DrugDiscovery #ScientificLeadership #DrGPCR Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- Exploring the combination of molecular simulation, pharmacological assays, and NMR to reveal the molecular mechanism of biased activation at the vasopressin V2 receptor. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! | Dr. GPCR Ecosystem
Home → Flash News → Exploring the combination of molecular simulation, pharmacological assays, and NMR to reveal the molecular mechanism of biased activation at the vasopressin V2 receptor. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! Published on December 10, 2024 Category GPCR Weekly News Exploring the combination of molecular simulation, pharmacological assays, and NMR to reveal the molecular mechanism of biased activation at the vasopressin V2 receptor. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-affinity-elr%2B-chemokine-ligands-show-g-protein-bias-over-%CE%B2-arrestin-recruitment-and-receptor-internalization-in-cxcr1-signalling #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on January 24, 2025 Category GPCR University In case you haven’t heard, our next Dr.GPCR University course is open for registrations 🙂 Learn about "The Practical Assessment of Signaling Bias" with Dr. Terry Kenakin. 🙌 Hands-on exercises included! ✳️Only 25 spots available ➡️Enjoy a 25% discount with your Premium Membership https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- 🚀 New Workshop: Practical Quantification of Allosteric Modulation Join Dr. Terry Kenakin on May 1st, 2025, for an advanced live workshop on allosteric modulators in GPCR drug discovery. Learn how to: ✔️ Identify, measure, and quantify allosteric properties ✔️ Apply functional allosteric models to determine mechanisms of action ✔️ Confirm allostery through kinetic analysis 📅 Date: May 1st, 2025 ⏳ Registration deadline: April 18th 📍 Live on Google Meet 🔗 Register now: https://www.ecosystem.drgpcr.com/event-details-registration/practical-quantification-of-allosteric-modulation #GPCR #Allostery #DrugDiscovery #Pharmacology | Dr. GPCR Ecosystem
Home → Flash News → 🚀 New Workshop: Practical Quantification of Allosteric Modulation Join Dr. Terry Kenakin on May 1st, 2025, for an advanced live workshop on allosteric modulators in GPCR drug discovery. Learn how to: ✔️ Identify, measure, and quantify allosteric properties ✔️ Apply functional allosteric models to determine mechanisms of action ✔️ Confirm allostery through kinetic analysis 📅 Date: May 1st, 2025 ⏳ Registration deadline: April 18th 📍 Live on Google Meet 🔗 Register now: https://www.ecosystem.drgpcr.com/event-details-registration/practical-quantification-of-allosteric-modulation #GPCR #Allostery #DrugDiscovery #Pharmacology Published on March 3, 2025 Category GPCR University 🚀 New Workshop: Practical Quantification of Allosteric Modulation Join Dr. Terry Kenakin on May 1st, 2025 , for an advanced live workshop on allosteric modulators in GPCR drug discovery. Learn how to: ✔️ Identify, measure, and quantify allosteric properties✔️ Apply functional allosteric models to determine mechanisms of action✔️ Confirm allostery through kinetic analysis 📅 Date: May 1st, 2025⏳ Registration deadline: April 18th📍 Live on Google Meet 🔗 Register now: https://www.ecosystem.drgpcr.com/event-details-registration/practical-quantification-of-allosteric-modulation #GPCR #Allostery #DrugDiscovery #Pharmacology Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- terrys corner model drug response | Dr. GPCR Ecosystem
Home → Flash News → terrys corner model drug response Published on July 10, 2025 Category Terry's Corner What if a single experimental snapshot could predict an entire in vivo drug profile in a range of organs? In Terry’s Corner latest lesson, discover how pharmacologic models do just that. From historical linkage theory to dynamic probability models, the comparison of data to theory will be discussed. 🟢 Read the full breakdown: ✳️ https://www.ecosystem.drgpcr.com/post/what-if-you-could-predict-drug-behavior-with-just-a-snapshot #GPCR #DrGPCR #pharmacology #DrugDiscovery #TerryKenakin #FoundationalScience Recent Articles Previous Next
- Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. | Dr. GPCR Ecosystem
Home → Flash News → Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. Published on December 12, 2024 Category GPCR Weekly News Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. ➡ https:// www.ecosystem.drgpcr.com/gpcr-binders-drugs-and-more/design-of-allosteric-modulators-that-change-gpcr-g-protein-subtype-selectivity #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery | Dr. GPCR Ecosystem
Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 10, 2025 Category Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery , you know that finding a promising candidate is just the start. A drug must also:✅ Be absorbed into the body✅ Reach the right target✅ Stay long enough to be effective✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Recent Articles Previous Next
- We’re proud to welcome Celtarys as our media partner! Known for their fluorescent ligand innovation, Celtarys is helping researchers make biology visible, faster, smarter, and with more precision. Their chemistry speaks the language of biology, and now, they’re speaking to the global GPCR community through this powerful collaboration. 🔗 Explore Celtarys on the Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #DrGPCR #GPCRtools #FluorescentLigands #BiotechInnovation | Dr. GPCR Ecosystem
Home → Flash News → We’re proud to welcome Celtarys as our media partner! Known for their fluorescent ligand innovation, Celtarys is helping researchers make biology visible, faster, smarter, and with more precision. Their chemistry speaks the language of biology, and now, they’re speaking to the global GPCR community through this powerful collaboration. 🔗 Explore Celtarys on the Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #DrGPCR #GPCRtools #FluorescentLigands #BiotechInnovation Published on June 4, 2025 Category Celtarys - Media Partner We’re proud to welcome Celtarys as our media partner! Known for their fluorescent ligand innovation, Celtarys is helping researchers make biology visible, faster, smarter, and with more precision. Their chemistry speaks the language of biology, and now, they’re speaking to the global GPCR community through this powerful collaboration. 🔗 Explore Celtarys on the Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #DrGPCR #GPCRtools #FluorescentLigands #BiotechInnovation Recent Articles Previous Next
- New biosensor technologies are shedding light on GPCR dynamics directly in cells, offering exciting possibilities for multiplexing and miniaturization! Curious about how these advances could impact drug discovery? Check out the latest review on GPCR biosensors. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! | Dr. GPCR Ecosystem
Home → Flash News → New biosensor technologies are shedding light on GPCR dynamics directly in cells, offering exciting possibilities for multiplexing and miniaturization! Curious about how these advances could impact drug discovery? Check out the latest review on GPCR biosensors. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! Published on October 24, 2024 Category GPCR Weekly News New biosensor technologies are shedding light on GPCR dynamics directly in cells, offering exciting possibilities for multiplexing and miniaturization! Curious about how these advances could impact drug discovery? Check out the latest review on GPCR biosensors. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/reviews/gpcr-biosensors-to-study-conformational-dynamics-and-signaling-in-drug-discovery #GPCR #DrGPCR #biosensor Recent Articles Previous Next
- irreversible drugs post 2 | Dr. GPCR Ecosystem
Learn why some inhibitors act long after dosing ends. Explore the kinetic principles behind persistent binding and smarter drug design. Home → Flash News → irreversible drugs post 2 Persistent binding ≠ just covalent. Published on October 24, 2025 Category Terry's Corner Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Recent Articles Previous Next
- How does a superagonist activate M2 muscarinic receptors? New simulations reveal the conformational changes from inactive to active states to highlighting how ligand dynamics drive GPCR activation! Catch the full story in the Ecosystem! https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/visualizing-agonist-induced-m2-receptor-activation-regulated-by-aromatic-ring-dynamics #GPCR #drGPCR #M2R #drugdiscovery #moleculardynamics | Dr. GPCR Ecosystem
Home → Flash News → How does a superagonist activate M2 muscarinic receptors? New simulations reveal the conformational changes from inactive to active states to highlighting how ligand dynamics drive GPCR activation! Catch the full story in the Ecosystem! https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/visualizing-agonist-induced-m2-receptor-activation-regulated-by-aromatic-ring-dynamics #GPCR #drGPCR #M2R #drugdiscovery #moleculardynamics Published on March 31, 2025 Category GPCR Weekly News How does a superagonist activate M2 muscarinic receptors? New simulations reveal the conformational changes from inactive to active states to highlighting how ligand dynamics drive GPCR activation! Catch the full story in the Ecosystem! https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/visualizing-agonist-induced-m2-receptor-activation-regulated-by-aromatic-ring-dynamics #GPCR #drGPCR #M2R #drugdiscovery #moleculardynamics Recent Articles Previous Next
- Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining | Dr. GPCR Ecosystem
Home → Flash News → Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Published on June 28, 2025 Category Terry's Corner Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Recent Articles Previous Next
- From aspiring doctor to GPCR scientist! 🔬In this episode, Ian Chronis shares his journey from med school dreams to a PhD in pharmacology, diving into the fascinating world of receptor signaling. Can you guess what’s his favorite GPCR? ✅ Hear his response: Ep 164 with Dr. Ian Chronis #SciencePodcast #GPCR #PhDLife #DrGPCR | Dr. GPCR Ecosystem
Home → Flash News → From aspiring doctor to GPCR scientist! 🔬In this episode, Ian Chronis shares his journey from med school dreams to a PhD in pharmacology, diving into the fascinating world of receptor signaling. Can you guess what’s his favorite GPCR? ✅ Hear his response: Ep 164 with Dr. Ian Chronis #SciencePodcast #GPCR #PhDLife #DrGPCR Published on April 17, 2025 Category Dr. GPCR Podcast From aspiring doctor to GPCR scientist! 🔬In this episode, Ian Chronis shares his journey from med school dreams to a PhD in pharmacology, diving into the fascinating world of receptor signaling. Can you guess what’s his favorite GPCR? ✅ Hear his response: Ep 164 with Dr. Ian Chronis #SciencePodcast #GPCR #PhDLife #DrGPCR Recent Articles Previous Next
- Disrupting VIPR2 dimerisation halts breast cancer spread—could TM3-4 peptides be the next breakthrough in targeted cancer therapy? Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https://www.ecosystem.drgpcr.com/gpcrs-in-oncology-and-immunology/dimerisation-of-the-vip-receptor-vipr2-is-essential-to-its-binding-vip-and-g%CE%B1i-proteins%2C-and-to-its-functions-in-breast-cancer-cells #gpcr#drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Disrupting VIPR2 dimerisation halts breast cancer spread—could TM3-4 peptides be the next breakthrough in targeted cancer therapy? Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https://www.ecosystem.drgpcr.com/gpcrs-in-oncology-and-immunology/dimerisation-of-the-vip-receptor-vipr2-is-essential-to-its-binding-vip-and-g%CE%B1i-proteins%2C-and-to-its-functions-in-breast-cancer-cells #gpcr#drgpcr Published on May 12, 2025 Category GPCR Weekly News Disrupting VIPR2 dimerisation halts breast cancer spread—could TM3-4 peptides be the next breakthrough in targeted cancer therapy? Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https://www.ecosystem.drgpcr.com/gpcrs-in-oncology-and-immunology/dimerisation-of-the-vip-receptor-vipr2-is-essential-to-its-binding-vip-and-g%CE%B1i-proteins%2C-and-to-its-functions-in-breast-cancer-cells #gpcr#drgpcr Recent Articles Previous Next
- An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr Published on February 19, 2025 Category Dr. GPCR Courses An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr Recent Articles Previous Next
- How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. open book Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR | Dr. GPCR Ecosystem
Home → Flash News → How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. open book Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Published on June 9, 2025 Category GPCR Weekly News How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Recent Articles Previous Next
- Do you know that dilated cardiomyopathy, a disease that makes it harder for the heart to pump blood to the rest of the body, results from the deficiency of Latrophilin-2? Check out this paper to understand the function of Latrophilin-2 and how it leads to dilated cardiomyopathy. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. | Dr. GPCR Ecosystem
Home → Flash News → Do you know that dilated cardiomyopathy, a disease that makes it harder for the heart to pump blood to the rest of the body, results from the deficiency of Latrophilin-2? Check out this paper to understand the function of Latrophilin-2 and how it leads to dilated cardiomyopathy. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. Published on October 31, 2024 Category GPCR Weekly News Do you know that dilated cardiomyopathy, a disease that makes it harder for the heart to pump blood to the rest of the body, results from the deficiency of Latrophilin-2? Check out this paper to understand the function of Latrophilin-2 and how it leads to dilated cardiomyopathy. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/latrophilin-2-deletion-in-cardiomyocyte-disrupts-cell-junction%2C-leading-to-d-cmp Recent Articles Previous Next
- The GPCR world is waiting to see YOU. Update your profile today and be part of the biggest GPCR community in the world 🌏 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and share your updated information 😉 #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → The GPCR world is waiting to see YOU. Update your profile today and be part of the biggest GPCR community in the world 🌏 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and share your updated information 😉 #gpcr #drgpcr Published on February 11, 2025 Category Dr. GPCR Profiles The GPCR world is waiting to see YOU. Update your profile today and be part of the biggest GPCR community in the world 🌏 ✳️ Visit https://www.ecosystem.drgpcr.com/account/my-account and share your updated information 😉 #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next
- Generic tools won’t solve tomorrow’s drug discovery challenges. That’s why Celtarys designs custom fluorescent probes for every target, built for real pharmacology, not just convenience. With Dr. GPCR and Celtarys joining forces, expect more visibility, more precision, and more scientific impact. 🚀 Get to know our media partner: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRdrugDiscovery #GPCRecosystem #CustomLigands | Dr. GPCR Ecosystem
Home → Flash News → Generic tools won’t solve tomorrow’s drug discovery challenges. That’s why Celtarys designs custom fluorescent probes for every target, built for real pharmacology, not just convenience. With Dr. GPCR and Celtarys joining forces, expect more visibility, more precision, and more scientific impact. 🚀 Get to know our media partner: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRdrugDiscovery #GPCRecosystem #CustomLigands Published on June 27, 2025 Category Celtarys - Media Partner Generic tools won’t solve tomorrow’s drug discovery challenges. That’s why Celtarys designs custom fluorescent probes for every target, built for real pharmacology, not just convenience. With Dr. GPCR and Celtarys joining forces, expect more visibility, more precision, and more scientific impact. 🚀 Get to know our media partner: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRdrugDiscovery #GPCRecosystem #CustomLigands Recent Articles Previous Next
- GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! | Dr. GPCR Ecosystem
Home → Flash News → GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! Published on October 22, 2024 Category GPCR Weekly News GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/germline-mutations-in-a-g-protein-identify-signaling-cross-talk-in-t-cells #GPCR #DrGPCR Recent Articles Previous Next
- Do you remember the first time you were left alone in the lab with an experiment? 🤔 Did your experience compare to Dr. Brian Hudson’s? 😄 Tune into this week’s Dr. GPCR Podcast for great stories, GPCR insights, and a fascinating journey that led Dr. Hudson to years of groundbreaking research at the University of Glasgow. Don’t miss out! ✅Listen now https://buff.ly/aEQGUFl #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Do you remember the first time you were left alone in the lab with an experiment? 🤔 Did your experience compare to Dr. Brian Hudson’s? 😄 Tune into this week’s Dr. GPCR Podcast for great stories, GPCR insights, and a fascinating journey that led Dr. Hudson to years of groundbreaking research at the University of Glasgow. Don’t miss out! ✅Listen now https://buff.ly/aEQGUFl #gpcr #drgpcr Published on March 17, 2025 Category Dr. GPCR Podcast Do you remember the first time you were left alone in the lab with an experiment? 🤔 Did your experience compare to Dr. Brian Hudson’s? 😄 Tune into this week’s Dr. GPCR Podcast for great stories, GPCR insights, and a fascinating journey that led Dr. Hudson to years of groundbreaking research at the University of Glasgow. Don’t miss out! ✅Listen now https://buff.ly/aEQGUFl #gpcr #drgpcr Recent Articles Previous Next
- 🚀 New Learning Opportunities at Dr.GPCR University! Expand your GPCR expertise with exclusive workshops, interactive courses, and an on-demand library—all in one place! ✅ Register for upcoming sessions ✅ Access expert-led content anytime ✅ Enjoy premium benefits & exclusive resources 📢 Don’t miss out—start your learning journey today! 🔗 https://www.ecosystem.drgpcr.com/gpcr-courses #GPCR #DrGPCR #LifelongLearning #drugdiscovery #pharmacology | Dr. GPCR Ecosystem
Home → Flash News → 🚀 New Learning Opportunities at Dr.GPCR University! Expand your GPCR expertise with exclusive workshops, interactive courses, and an on-demand library—all in one place! ✅ Register for upcoming sessions ✅ Access expert-led content anytime ✅ Enjoy premium benefits & exclusive resources 📢 Don’t miss out—start your learning journey today! 🔗 https://www.ecosystem.drgpcr.com/gpcr-courses #GPCR #DrGPCR #LifelongLearning #drugdiscovery #pharmacology Published on February 25, 2025 Category GPCR Weekly News 🚀 New Learning Opportunities at Dr.GPCR University! Expand your GPCR expertise with exclusive workshops, interactive courses, and an on-demand library—all in one place! ✅ Register for upcoming sessions ✅ Access expert-led content anytime ✅ Enjoy premium benefits & exclusive resources 📢 Don’t miss out—start your learning journey today! 🔗 https://www.ecosystem.drgpcr.com/gpcr-courses #GPCR #DrGPCR #LifelongLearning #drugdiscovery #pharmacology Recent Articles Previous Next
- Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox Unlocking the activation process of PTH1R: New computational insights into its molecular interactions bring us closer to better osteoporosis treatments! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/key-interaction-changes-determine-the-activation-process-of-human-parathyroid-hormone-type-1-receptor #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox Unlocking the activation process of PTH1R: New computational insights into its molecular interactions bring us closer to better osteoporosis treatments! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/key-interaction-changes-determine-the-activation-process-of-human-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Published on February 6, 2025 Category GPCR Weekly News Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox Unlocking the activation process of PTH1R: New computational insights into its molecular interactions bring us closer to better osteoporosis treatments! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/key-interaction-changes-determine-the-activation-process-of-human-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Recent Articles Previous Next
- Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology | Dr. GPCR Ecosystem
Home → Flash News → Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Published on June 3, 2025 Category Dr. GPCR Podcast Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Recent Articles Previous Next
- "Solving financial puzzles feels just like solving scientific ones," says Joe St. Germain from Company Launch Partners. Behind every successful research organization, there is a rock-solid operations team. Don’t miss this rare conversation bridging science, structure, and strategy with Chuck DeWeese & Joe St. Germain. ✳️ Tune in now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup | Dr. GPCR Ecosystem
Home → Flash News → "Solving financial puzzles feels just like solving scientific ones," says Joe St. Germain from Company Launch Partners. Behind every successful research organization, there is a rock-solid operations team. Don’t miss this rare conversation bridging science, structure, and strategy with Chuck DeWeese & Joe St. Germain. ✳️ Tune in now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on May 1, 2025 Category Dr. GPCR Podcast "Solving financial puzzles feels just like solving scientific ones," says Joe St. Germain from Company Launch Partners.Behind every successful research organization, there is a rock-solid operations team. Don’t miss this rare conversation bridging science, structure, and strategy with Chuck DeWeese & Joe St. Germain. ✳️ Tune in now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Recent Articles Previous Next
- Forget one receptor at a time. Go big.Ep.167 of the Dr.GPCR Podcast with Tom Sakmar & Ilana Kotliar is about scaling GPCR research with multiplexing, miniaturization, and collaboration. The tools are built. The data is free. What will you ask next? 📲 Dive in: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRtraining #GPCRresearchcommunity #DrGPCR #GPCRdata | Dr. GPCR Ecosystem
Home → Flash News → Forget one receptor at a time. Go big.Ep.167 of the Dr.GPCR Podcast with Tom Sakmar & Ilana Kotliar is about scaling GPCR research with multiplexing, miniaturization, and collaboration. The tools are built. The data is free. What will you ask next? 📲 Dive in: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRtraining #GPCRresearchcommunity #DrGPCR #GPCRdata Published on June 5, 2025 Category Dr. GPCR Podcast Forget one receptor at a time. Go big.Ep.167 of the Dr.GPCR Podcast with Tom Sakmar & Ilana Kotliar is about scaling GPCR research with multiplexing, miniaturization, and collaboration. The tools are built. The data is free. What will you ask next? 📲 Dive in: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRtraining #GPCRresearchcommunity #DrGPCR #GPCRdata Recent Articles Previous Next
- ep 169 with sokhom pin some 2 | Dr. GPCR Ecosystem
Home → Flash News → ep 169 with sokhom pin some 2 Published on July 10, 2025 Category Dr. GPCR Podcast Build the team you always wished you had. At Alkermes, Sokhom S. Pin didn’t just lead a lab. He built a culture. His team became known as “the happiest group in the company.” Why? Empowerment, trust, and zero tolerance for toxicity. It wasn’t luck. It was leadership. ✳️ Watch Ep. 169: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #biotechleadership #GPCRresearchcommunity #DrGPCR #teamculture Recent Articles Previous Next